Abstract: The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans.

Abstract: Embodiments of the invention provide an array substrate, a manufacturing method thereof and a display device. The array substrate comprises: a base substrate; a gate line and a gate electrode formed on the base substrate; a gate insulating layer formed on the gate line and the gate electrode; a source electrode, a drain electrode and a pixel electrode formed on the gate insulating layer, wherein the pixel electrode is directly connected to the drain electrode; and an active layer formed on the gate insulating layer, the source electrode and the drain electrode.

Abstract: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

Abstract: The development of a series of fluorescent materials including heterocycle-functionalized luminogens with aggregation-induced/enhanced emission (AIE/AEE), long wavelength emission, and high solid state fluorescence quantum efficiency is contemplated. The described fluorescent materials are promising candidates in selective luminescence-based chemosensor for Hg2+ or ATP, fluorescent staining for mitochondria in living cells with high photostability, stimuli-responsive luminescent materials, and materials for optical waveguides. In addition, these heterocycle-functionalized luminogens are particularly useful as fluorescent labels for biopolymers such as peptides, antibodies, or nucleic acids, making them useful as AIE-active biocompatible probes for clinical cancer imaging and diagnostics.

Abstract: Disclosed are films which can provide seal strengths suited for both peelable and nonpeelable seals in a package.

Abstract: The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.

Abstract: The development of a series of fluorescent materials including heterocycle-functionalized luminogens with aggregation-induced/enhanced emission (AIE/AEE), long wavelength emission, and high solid state fluorescence quantum efficiency is contemplated. The described fluorescent materials are promising candidates in selective luminescence-based chemosensor for Hg2+ or ATP, fluorescent staining for mitochondria in living cells with high photostability, stimuli-responsive luminescent materials, and materials for optical waveguides. In addition, these heterocycle-functionalized luminogens are particularly useful as fluorescent labels for biopolymers such as peptides, antibodies, or nucleic acids, making them useful as AIE-active biocompatible probes for clinical cancer imaging and diagnostics.

Abstract: The present disclosure is related to semiconductor technologies and discloses a semiconductor device and its method of making. In the present disclosure, a transistor's source and drain are led out by forming vias or contact holes in an insulator layer covering the transistor and at metal silicide contact regions corresponding to the source and drain, and by filling the vias with metal-semiconductor compound. Because the metal-semiconductor compound has relatively low resistivity, the resistance of the material in the vias can be minimized. Also, because the material used to fill the vias and the material forming the source/drain contact regions are both metal-semiconductor compound, contact resistance between the material filling the vias and the source/drain contact regions can be minimized.

Abstract: The application of aqueous solution of magnesium bicarbonate and/or calcium bicarbonate in the process of extraction separation and purification of metals is disclosed, wherein the aqueous solution of magnesium bicarbonate and/or calcium bicarbonate is used as an acidity balancing agent, in order to adjust the balancing pH value of the extraction separation process which uses an acidic organic extractant, improve the extraction capacity of organic phase, and increase the concentration of metal ions in the loaded organic phase.

Abstract: Embodiments of the invention provide an array substrate, a manufacturing method thereof and a display device. The array substrate comprises: a base substrate; a gate line and a gate electrode formed on the base substrate; a gate insulating layer formed on the gate line and the gate electrode; a source electrode, a drain electrode and a pixel electrode formed on the gate insulating layer, wherein the pixel electrode is directly connected to the drain electrode; and an active layer formed on the gate insulating layer, the source electrode and the drain electrode.

Abstract: A control of a multi-variable process throughout a plurality of successive, distinct operational phases of the process involves accumulation of sets of values of the process and quality variables (a-j) from previous multiple operations of the process through all its phases, as respective datasets of a historical record. Each dataset includes an identifier (p) of the phase to which it relates. The current values of the applicable process variables (Qa-Qh) during each phase and the phase identifier (p) are indicated on respective axes (Xp,Xa-Xh) of a multi-dimensional display in relation to an operational envelope which defines bounds (UL,LL) for the values of the individual process and quality variables (a-j) relevant to that phase and which is derived from the datasets of the historical record identified with that phase. Changes in the current process variables (Qa-Qh) result in changes of the bounds (UL,LL), and alarm is given when a current value departs from within them.

Abstract: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

Abstract: The application of aqueous solution of magnesium bicarbonate and/or calcium bicarbonate in the process of extraction separation and purification of metals is disclosed, wherein the aqueous solution of magnesium bicarbonate and/or calcium bicarbonate is used as an acidity balancing agent, in order to adjust the balancing pH value of the extraction separation process which uses an acidic organic extractant, improve the extraction capacity of organic phase, and increase the concentration of metal ions in the loaded organic phase.

Abstract: A control of a multi-variable process throughout a plurality of successive, distinct operational phases of the process involves accumulation of sets of values of the process and quality variables (a-j) from previous multiple operations of the process through all its phases, as respective datasets of a historical record. Each dataset includes an identifier (p) of the phase to which it relates. The current values of the applicable process variables (Qa-Qh) during each phase and the phase identifier (p) are indicated on respective axes (Xp,Xa-Xh) of a multi-dimensional display in relation to an operational envelope which defines bounds (UL,LL) for the values of the individual process and quality variables (a-j) relevant to that phase and which is derived from the datasets of the historical record identified with that phase. Changes in the current process variables (Qa-Qh) result in changes of the bounds (UL,LL), and alarm is given when a current value departs from within them.

Abstract: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

Abstract: A process for pretreating organic extractants and its product and application in SX separation of rare earth. The pretreating method is that extractant and rare earth solution are mixed with powder or slurry of alkaline earth metal compound containing magnesium and/or calcium to realize pre-extraction, or the organic extractant are mixed with rare earth carbonate slurry to realize pre-extraction. When rare earth ion in aqueous phase is extracted into organic phase, the exchanged hydrogen ions enter into aqueous phase and dissolve the alkaline earth metal compound or the rare earth carbonate which helps to keep the acidity equilibrium of the system. The obtained organic extractant loaded with rare earth is used for unsaponificated SX separation of rare earth. With this method, there is no need to saponificate organic extractant with liquid ammonia or alkali, and there is no ammonia-nitrogen wastewater produced. So separation cost decrease at a large scale and a lot of the cost to treat the three wastes is cut.

Abstract: The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).

Abstract: The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).